Agoracom Blog Home

Posts Tagged ‘Hemp’

TransCanna $TCAN.ca and Award-Winning Product Producers, the Summit Boys, to Co-Brand #Cannabis Concentrates $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:11 AM on Tuesday, July 21st, 2020
tcan-square
  • Announced a Memorandum of Understanding with award-winning and leading legacy cannabis brand, the Summit Boys, to co-brand a series of high-quality cannabis concentrates
  • Summit Boys are a well-known legacy recreational cannabis product producers (operating since 2016 under prop 215 and with a cult-like following on Instagram of over 66,000 followers).
  • Demand for Cannabis Concentrates are the Fastest Growing of all Related Product Categories

Vancouver, British Columbia–(July 21, 2020) – TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company”) is pleased to announce a Memorandum of Understanding with award-winning and leading legacy cannabis brand, the Summit Boys, to co-brand a series of high-quality cannabis concentrates.

The Summit Boys are a well-known legacy recreational cannabis product producers (operating since 2016 under prop 215 and with a cult-like following on Instagram of over 66,000 followers). In this agreement, Lyfted Farms (a TransCanna subsidiary), will supply high-quality cannabis flower to the Summit Boys for processing into a line of popular cannabis concentrates branded as ‘Caviar.’

In 2019, the Summit Boys earned 14 awards in the Bay Area Cannabis Cup in several categories, including for Best Product and Hybrid Concentrate for this same Caviar product. The line of ‘White Caviar’ branded products are what The Summit Boys are best known for.

Cannabis concentrates have a greater proportion of cannabinoids and terpenes when compared to natural cannabis flowers, and can increase the potency of cannabis flower. Demand for these concentrates are also the fastest-growing of any cannabis product in the California market (the largest Cannabis market globally).

“This co-branding of the already famous Caviar product now powered by Lyfted’s flower is great news for cannabis consumers,” says Bob Blink, TransCanna CEO. “For us, it’s another example of our strategy to align with high-quality producers and already successful players in the industry-this time with the added value of the Summit Boys’ grassroots following. But for the more sophisticated California cannabis market, this partnership will mean an even higher quality product for consumers.”

“As a dedicated brand to California Cannabis market, we wanted to find like-minded partners. Since meeting the Lyfted team, they have earned our respect, and we definitely look forward to working together. There are many things that excite us, but being able to co-brand and scale now that the Daly Facility is licensed is a huge opportunity, ” stated Mike Larson, Summit Boys CEO.

News of this agreement follows an announcement by TransCanna that the Company was awarded its final operating license for the 196,000 square foot Daly Facility by the California Bureau of Cannabis Control July 10, 2020.

About TransCanna Holdings Inc.

TransCanna Holdings Inc. is a California based, Canadian listed company building Cannabis-focused brands for the California lifestyle, through its wholly-owned California subsidiaries.

For further information, please visit the Company’s website at www.transcanna.com or email the Company at [email protected].

On behalf of the Board of Directors,

Bob Blink, CEO
604-349-3011

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs regarding future events of management of the Company. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. This information and these statements, referred to herein as “forward-looking statements”, are not historical facts, are made as of the date of this news release and include without limitation estimates and forecasts and statements as to management’s expectations for growth and the commencement of operations of the Company’s Daly facility.

The forward-looking information in this press release is based upon certain assumptions that management considers reasonable in the circumstances, including that operations will commence at the Company’s Daly facility in Modesto, California, as and when expected.

These forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially from any future results, events or developments expressed or implied by such forward-looking statements. Risks and uncertainties associated with the forward-looking information in this news release include, among others, dependence on obtaining and maintaining regulatory approvals, including state, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to complete upgrades to its Daly facility in a timely manner; engaging in activities which currently are illegal under U.S. federal law and the uncertainty of existing protection from U.S. federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including U.S. state-law legalization, particularly in California, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth;; reliance on management; and the effect of capital market conditions and other factors (including those related to the COVID-19 pandemic) on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look, except in accordance with applicable securities laws.

Empower Clinics $CBDT.ca Announces Closing of Private Placement Increased Demand for COVID-19 Testing and Are on Pace for Record July Patient Visits $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 1:29 PM on Thursday, July 16th, 2020
  • Closes private placement of $720,866.00 to support the Company growth plan
  • Continues to meet increased demand for COVID-19 testing in Arizona clinics, along with supporting record patient demand in July 2020

VANCOUVER, BC / July 16, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) (“Empower” or the “Company“), a life sciences company, is pleased to announce the closing of its non-brokered private placement of an aggregate of 14,417,334 units of the Company (each, a “Unit“) at a price of $0.05 per Unit for gross proceeds of $720,866.00 (the “Offering“).

The proceeds of the Offering are expected to be used by the Company for general working capital and corporate purposes and to support the launch if it’s previously announced psychedelics division Dosed Wellness Ltd. www.dosedwellness.com

The Company also continues to see strong demand for COVID-19 testing supported by an expansion to five-day per week testing schedule in Phoenix, AZ clinics. In addition, Sun Valley Health has added ten (10) new hires and (4) internal management promotions in the past 30 days to manage the increased volumes of patients, that are anticipated to reach record levels in July 2020.

“Our clinic team continue to provide exemplary support and care for patients, in a safe and compassionate manner,” said Steven McAuley, Chairman & CEO. “Successfully accessing the capital markets to support growth allows the Company to advance its ongoing plan of providing diversified health & wellness services and positioning us to become a long-term market leader.”

Each Unit is comprised of one Share and one Warrant, with each Warrant exercisable into one Warrant Share at an exercise price of $0.12 per Warrant Share for a period of two years following the Closing.

The Units, and the underlying Shares, Warrants and Warrant Shares (collectively, the “Securities“), are subject to restrictions on resale under applicable Canadian securities laws for a period of four months and one day from the closing of the Offerings. None of the Securities have been or will be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities, in any jurisdiction in which such offer, solicitation or sale would require registration or otherwise be unlawful.

ABOUT EMPOWER

Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

Investors: Dustin Klein
Director
dustin@svmmjcc,com
720-352-1398

Investors: Steven McAuley
CEO
[email protected]
604-789-2146

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

TransCanna $TCAN.ca Commences “Phase 1” Construction and Roll-Out of Commercial Activities at Flagship Daly Facility $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:01 AM on Thursday, July 16th, 2020
tcan-square
  • Begun preparations for the commercial launch of distribution activities at its flagship 196,000 square foot Daly Avenue Facility in Modesto California
  • Goal of Phase 1 is to focus on expansion and ramp-up of the companies’ distribution activities
  • Revised design of Phase 1 of the Daly Distribution build-out increases capacity by 16,000 square feet, allowing the Company to expand this core business unit to service escalating demand from customers

Vancouver, British Columbia–(July 16, 2020) – TransCanna Holdings Inc. (CSE: TCAN) (XETR: TH8) (“TransCanna” or the “Company”) is pleased to announce that with the recent state-wide final license approval, today its wholly-owned subsidiary, Lyfted Farms, Inc. (“Lyfted”), has begun preparations for the commercial launch of distribution activities at its flagship 196,000 square foot Daly Avenue Facility in Modesto California.

The goal of Phase 1 is to focus on expansion and ramp-up of the companies’ distribution activities. The revised design of Phase 1 of the Daly Distribution build-out increases capacity by 16,000 square feet, allowing the Company to expand this core business unit to service escalating demand from customers.

“After many months of planning and preparation, our team is thrilled to begin operations inside of Daly,” said CEO Bob Blink. “We look forward to rewarding our investors’ patience with this initial phase and present the true potential we believe The Daly Building has to offer. As early as Q4 2020, we expect to see an incremental increase in revenue from Distribution activities in the vicinity of $6,000,000 CDN per quarter. When combined with existing revenues, our target run-rate by our fiscal year-end should exceed previous projections and be in the neighborhood of $36,000,000 CDN.”

Lyfted Farms has accepted a contract with Bay Alarm Company to install a state of the art, integrated security system in preparation for commercial activity at the Daly facility. Pre-site preparations are underway, and system completion is expected by August 15, 2020.

Additionally, the facility’s triple-redundancy heating, ventilation, and air conditioning “HVAC,” sub-forty-degree Fahrenheit freezer, and distribution area systems have been activated for pre-cooling and calibration within the areas of operation. Employee technician training has started on the Company’s high speed automated packaging systems, combining WeighPack Swifty Baggers and Combiscale 14-head rotary scales to provide high-efficiency and precision filling, which reduce labor and material costs to industry-leading levels.

Packaging and support materials began arriving this week into the Daly distribution center with completion of the Phase 1 Distribution build-out expected by September 15, 2020.

About TransCanna Holdings Inc.

TransCanna Holdings Inc. is a California based, Canadian listed company building Cannabis-focused brands for the California lifestyle, through its wholly-owned California subsidiaries.

For further information, please visit the Company’s website at www.transcanna.com or email the Company at [email protected].

On behalf of the Board,

Bob Blink, CEO
604-349-3011

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs regarding future events of management of the Company. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. This information and these statements, referred to herein as “forward‐looking statements”, are not historical facts, are made as of the date of this news release and include without limitation estimates and forecasts and statements as to management’s expectations for growth and the commencement of operations of the Company’s Daly facility.

The forward-looking information in this press release is based upon certain assumptions that management considers reasonable in the circumstances, including that operations will commence at the Company’s Daly facility in Modesto, California as and when expected.

These forward‐looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially from any future results, events or developments expressed or implied by such forward-looking statements. Risks and uncertainties associated with the forward looking information in this news release include, among others, dependence on obtaining and maintaining regulatory approvals, including state, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to complete upgrades to its Daly facility in a timely manner; engaging in activities which currently are illegal under U.S. federal law and the uncertainty of existing protection from U.S. federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including U.S. state-law legalization, particularly in California, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth;; reliance on management; and the effect of capital market conditions and other factors (including those related to the COVID-19 pandemic) on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look, except in accordance with applicable securities laws.

Hollister Biosciences $HOLL.ca Provides Update on Q2 2020, Generated Record Quarterly Revenue of CDN$ 11.5 Million and Announces Distribution License Renewal $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 8:05 PM on Tuesday, July 14th, 2020
  • Generated record quarterly revenue of CDN$ 11.5 million,
  • CDN$ 1.375 million in EBITDA
  • Bureau of Cannabis Control officially renewed its cannabis distribution license for the next year through August 2021

VANCOUVER, BC, July 14, 2020 – Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the “Company“, “Hollister Cannabis Co.” or “Hollister“) a diversified cannabis branding company with products in over 230 dispensaries throughout California, and over 80 dispensaries throughout Arizona,  is pleased to provide an update on its Q2, 2020 performance as well as announce that the Bureau of Cannabis Control (“BCC“) officially renewed its cannabis distribution license for the next year through August 2021.

Q2 2020 Update

For the period beginning April 1st, 2020 and ending June 30th, 2020, Hollister reports that it generated record quarterly revenue of CDN$ 11.5 million and CDN$ 1.375 million in EBITDA from its product line of pre-rolls, concentrates, distillates, solvent-free bubble hash, pre-packaged flower, tinctures and vape products.  The Company cautions that revenue and EBITDA figures have not yet been audited and are based on reports prepared by management.

“We are very pleased with our revenue growth year to date.  Sales of cannabis related products have proven to be resilient throughout the COVID-19 pandemic.  We hope to continue to deliver strong results as the year progresses” stated Carl Saling, CEO.

About the BCC

The Bureau of Cannabis Control is the lead agency in regulating commercial cannabis licenses for medical and adult-use cannabis in California. The BCC is responsible for licensing retailers, distributors, testing laboratories, microbusinesses, and temporary cannabis events. A distributor (Type 11) licensee is responsible for transporting cannabis goods between licensees, arranging for testing of cannabis goods, and conducting the quality assurance review of cannabis goods to ensure compliance with all packaging and labeling requirements. A licensed distributor may only distribute cannabis goods, cannabis accessories, and licensees’ branded merchandise or promotional materials.

“Our distribution license is a critical component to our California operation, and we are honored to have had our license renewed by the BCC” stated Carl Saling, CEO.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products.  Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

INTERVIEW: TransCanna $TCAN.ca License Creates One Of California’s Largest Fully Licensed Cannabis Facilities $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 8:12 PM on Sunday, July 12th, 2020
tcan-square

TransCanna Holdings (TCAN:CSE) is part of the New Cannabis Kids On The Block wave that investors are demanding after mega financed companies flopped last year.  TCAN, on the other hand, is delivering the following to investors: 

·  $2M CAD Revenue April 2020 

·  $24.6M CAD Revenue Run Rate solely from TransCanna test facility 

·  $90M Annual Revenue expected from first full year upon completion of 196,000 Sq Ft Daly facility Q3 2021 

·  Daly facility will be one of the largest cannabis facilities in California 

And today the story got even better, with TCAN announcing that its wholly-owned subsidiary was granted a “Type 11 Distributor License” by the California Bureau of Cannabis Control for its 196,000 square foot Daly Avenue Facility. 

HUGE BUSINESS IMPLICATIONS – TRANSCANNA POSITIONED TO BECOME PART OF NEW LEADERSHIP GROUP IN CANNABIS  

As a result, Trancanna now owns the largest known, fully licensed cannabis facility in California.  Given the fact TCAN is processing more than $USD 1,000,000/month in wholesale cannabis transactions out of a distribution space of just 1,000 square feet, the implications for Daly expanding to 196,000 square feet are HUGE in the areas of:  

  • Capacity 
  • Revenue
  • Reach
  • …. much more 

The first round of cannabis leaders disappointed investors and created significant value destruction in the space.  But like every new mega industry that goes through a catharsis stage, the next round of growth gives birth to the best and potentially biggest players for the long haul.

The next 24 – 36 months are going to be fun for TCAN.  How fun?  Watch this interview with CEO Bob Blink.

Watch this interview or listen by Podcast on AppleGoogleSpotify or your favourite podcaster.

TransCanna Receives State-Wide Operating License $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:49 PM on Sunday, July 12th, 2020
tcan-square
  • Successfully granted a Type 11 ‘Distributor’ license by the California Bureau of Cannabis Control for its 196,000 square foot Daly Avenue Facility
  • Now owns largest known fully licensed cannabis facilities in California
  • “This is the most exciting development in our history and what everyone has been working towards,” says Bob Blink, TransCanna CEO

Vancouver, British Columbia–(July 11, 2020) – TransCanna Holdings Inc. (CSE: TCAN) (FSE: XETR) (“TransCanna” or the “Company”) is pleased to announce that its wholly-owned subsidiary, Lyfted Farms, Inc. (“Lyfted”), was successfully granted a Type 11 ‘Distributor’ license by the California Bureau of Cannabis Control for its 196,000 square foot Daly Avenue Facility.

This long-anticipated milestone marks the completion of all state and local licenses required for the Company to begin operations at its flagship cannabis processing facility in Modesto, California.

This state-wide license represents Lyfted’s most major milestone to date in meeting the distribution and production capabilities needed to meet the escalating demand for its products in the world’s largest cannabis market. The license was granted after three levels of approvals were achieved at the county and state level and will allow for the commencement of packaging, transport, wholesale, pre-roll assembly, labeling, testing, contract packaging (white-labeling), and of course distribution of cannabis products to all licensed retailers across the state.

“This is the most exciting development in our history and what everyone has been working towards,” says Bob Blink, TransCanna CEO. “Being granted a license at the state level is a long, costly, and complex process, and one that requires navigating and understanding a complex regulatory process. It’s a significant barrier to entry for most companies, so this marks a huge turning point for us. We are delighted to have achieved our biggest goal to date and excited to be able to better serve the demands of the California cannabis market.”

The Company is currently completing upgrades to the flagship Daly Facility. Commercial cannabis activities are expected to commence at Daly August 2020, via the deployment of a 16,000 square foot cannabis distribution center (Phase 1). To date, Lyfted has been able to process in excess of $1M USD/month in wholesale cannabis transactions out of a distribution space of 1,000 square feet from its Jerusalem Court facility. These upgrades will mean the Company now has 16,000 square feet of distribution space at its disposal as of August 2020.

“This exponential increase in capacity is incredibly exciting for investors,” says Blink, adding the Company has been focused on building out its wholesale and distribution business while awaiting its final license. “Having processed a million dollars’ worth of product out of a single one-thousand square foot facility, we are anticipating significant growth now that our 196,000 square foot operation is online.”

Lyfted anticipates hiring up to 250 full-time employees at the flagship site with a strong focus placed on social equity and a diverse workforce that is reflective of the communities it serves and operates in.

About TransCanna Holdings Inc.

TransCanna Holdings Inc. is a California based, Canadian listed company building cannabis-focused brands for the California lifestyle, through its wholly-owned California subsidiaries.

For further information, please visit the Company’s website at www.transcanna.com or email the Company at [email protected].

On behalf of the Board of Directors

Bob Blink, CEO
604-349-3011

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Mota Ventures $MOTA.ca Reports $7.65m Revenue in Q1 2020 $SHRM $RVV $APH.ca $GBLX $PFE $WEED.ca $HIP.ca $WMD.ca

Posted by AGORACOM at 8:07 AM on Wednesday, July 8th, 2020

VANCOUVER, BC / ACCESSWIRE / July 8, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC PINK:PEMTF) (the “Company“) is pleased to announce its financial results for the first quarter ending March 31, 2020. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated. The press release is intended to be read in conjunction with the Company’s unaudited Condensed Interim Consolidated Financial Statements and Management Discussion & Analysis for the three months ended March 31, 2020, which are filed under the Company’s profile on SEDAR (www.sedar.com), and also available on the Company’s website.

First Quarter 2020 Key Highlights include:

  • The Company acquired online cannabidiol (CBD) product distributor Nature’s Exclusive from Unified Funding, LLC.
  • Agreement finalized with Sativida OU (Estonia) and Sativida OU’s subsidiary, VIDA BCN LABS S.L (collectively, “Sativida”) to acquire Sativida in stages.
  • The Company acquired the intellectual property and trade names of Sativida in Spain, which will be licensed back in exchange for a royalty associated with gross revenues generated by Sativida.
  • The Company entered into a Licensing and Royalty Agreement with Phenome One Corporation (“Phenome”) for the right to cultivate, harvest, process and sell a selection of cultivars from Phenome’s genetic library, and the Company was granted unlimited access to a Phenome’s proprietary nutrient intellectual property (IP) and catalogue.
  • The Company entered into a Joint Venture with BevCanna Enterprises Inc (“BevCanna”) to distribute BevCanna branded beverage products infused with hemp-derived CBD in the European market.
  • Consolidated Q1 2020 gross revenue was $7.65 million, with cost of goods sold of $7.05 million, resulting in gross profits of $605,150. Operating and other operating expenses for the three months ended March 31, 2020 were $5.24 million.
  • The Company raised $1.72 million through share subscriptions received for the issuance of units at $0.28 and received $309,000 in proceeds from the exercise of warrants.
  • The Company ended Q1 2020 with $2.1 million in cash.

Management Commentary

In the midst of evolving challenges resulting from the global novel coronavirus outbreak, the Company realigned priorities to include focus on the health and safety of our employees, customers and suppliers. The way our team adapted and performed was exceptional. I am also pleased to announce that, despite the unprecedented uncertainties resulting from the coronavirus, our operations and supply chains performed without interruption, and the Company achieved targets in line with expectations. In order to capitalize on the global market, we recognize the need to be flexible and proactive in addressing market trends. For the second quarter our objectives are to yield increased revenues and higher gross margins. Due to the initial cost of customer acquisition, transitioning more customers into our monthly subscription will significantly increase margins.” stated Ryan Hoggan CEO of the Company.

About Mota Ventures Corp.

Mota Ventures is an established natural health products and eCommerce technology company focusing on the CBD and psychedelic medicine sectors. The company has a strong presence in both North America and Europe. In the United States, Mota Ventures offers a CBD hemp-oil product line derived from hemp grown and formulated in the US through its Nature’s Exclusive brand. Within Europe, the company’s Verrian operations is currently conducting clinical studies utilizing proprietary products for the treatment of opiate addiction. The highly skilled Verrian team also manages Mota Ventures’ 110,000 square foot manufacturing facility in Radebeul, Germany. In addition, Mota Ventures’ Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. The company is also seeking to acquire additional revenue-producing natural health product brands and operations in both Europe and North America with the goal of establishing an international distribution network utilizing its eCommerce technology platform.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.

Ryan Hoggan

Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Empower Clinics $CBDT.ca – 5 positive testimonials on medical marijuana benefits from real patients $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 4:30 PM on Monday, July 6th, 2020

SPONSOR:

Why Empower Clinics

  • A leading owner/operator of physician staffed health and pain management clinics.
  • Patient database of over 165,000 patients 
  • Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
  • Recently launched CBD extraction facility
  • First extraction system capacity = 2,300 Kg per year.
  • CBD based products are poised to be a $20B global industry by 2022
  • Medical cannabis is poised to be a $100B global industry by 2025
  • Company to Create Psilocybin and Psychadelics Division Leveraging Corporate Wellness Clinics and Franchise Clinic
  • Commenced tele-medicine services for patients, both in-clinics and virtually through secure video, on browser and in mobile app
  • Successfully conducted COVID-19 antibody business employee testing, solidifying the importance of phase three of the testing program
  • Conducted 2,302 physician-patient consultations setting a new milestone in patient volume for the month of May

—————————

5 positive testimonials on medical marijuana benefits from real patients

By: Pearce Thompson

We’d like to shine a light on a few patients in this article, to share their insights and experiences on how medical marijuana has benefited them throughout their illness. Please take the time to read through the list of 5 testimonials from real patients who have had positive outcomes from using the herb for their treatments.

If you want to view the history of medical marijuana referenced above, click here. If you want a timeline of the history of medical marijuana use in Canada, click here.

#1 Rebecca Swell an advocate of medical marijuana

When Rebecca was 10 years old she was diagnosed with Complex Regional Pain Syndrome, this condition comes from damage to the nervous system and causes extreme pain. Rebecca was forced into a walker or wheelchair from a young age, and when spinal cord stimulation and morphine didn’t work, she tried medical marijuana. Rebecca now needs no walking support, no morphine, and is an advocate of medical marijuana.

#2 Charlotte Figgi (Charlotte’s Web)

The story of Charlotte Figgi is more well known than most. Charlotte was diagnosed with a rare form of epilepsy at a young age and at 5 she experienced close to 300 mal seizures per week. The condition was so bad the doctor put her in a medically induced coma. In the first week of trying cannabis oil, Charlotte had no seizures. The strain created for her has no psychoactive effects and was renamed “Charlotte’s Web“.

#3 Ashley Surin

Ashly was diagnosed with Acute Lymphoblastic Leukemia, a type of cancer that affects white blood cells which makes it harder to fight infections. Ashley was also prone to seizures and her family moved to cannabis oil to aid this. The oil proved effective and is still used by Ashley to this day.

#4 Walter Rodlund

Walter Rodlund is from Fargo, ND and at the age 81 he enjoyed spending time outdoors his entire life. At this time he was diagnosed with Chronic Obstructive Pulmonary Disease, which decreased his lung capacity. With this condition, Walter could no longer enjoy the outdoors. His daughter recommended cannabis oil, Walter tried, Walter liked, Walter enjoys the outdoors again.

5. Beyla Pagano benefitted a lot by taking medical marijuana

From birth, Beyla had a large amount of cerebrospinal fluid built up in her brain. This caused seizures and doctors believed she would never walk or talk. The prescriptions given to her always put her in a drowsy state, so her family tried medical marijuana. The cannabis oil immediately improved her state, Beyla can walk, talk, and has seizures less frequently.

Empower $CBDT.ca #Covid19 Testing to Expand to Five Days Per Week and June 2020 Patient Visits Set Records $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 8:23 AM on Friday, July 3rd, 2020
  • Empower is expanding its COVID-19 testing to five days per week to meet demand
  • June 2020 patient volume surpasses 2,100 patients visits, a company record for the month of June

VANCOUVER, BC / July 3rd, 2020 / EMPOWER CLINICS INC. (CSE:CBDT) (OTCQB:EPWCF) (Frankfurt:8EC) (“Empower” or the “Company“), a life sciences company, is pleased to announce the Company is expanding COVID-19 testing days to meet the increasing demand in the State of Arizona. In addition, the Company conducted 2,130 physician-patient consultations setting a new historic milestone in patient volume for the month of June.

“As a company and a health & wellness clinic operator, we are fortunate to be able to provide care and support to our thousands of patients each month.” said Steven McAuley, Chairman & CEO of Empower. “The demand for our services, are at an all-time high, requiring us to hire new staff and extend hours of operation. Our team continues to perform with complete professionalism, and safety, knowing the importance of the physician consultations we provide.”

The Arizona Department of Health Services has reported that in the last seven (7) days, nearly 25,000 positive cases of coronavirus have been reported, representing more than 25% of the total cases in the state of Arizona since the pandemic first started in late January 2020. Total reported cases now exceed 87,000 in the state.

As previously disclosed, the Company submitted an application for a management cease trade order (“MCTO“) with the British Columbia Securities Commission. The Company confirms that the BC Securities Commission has approved the application for the MCTO effective June 16, 2020

As required under section 9 b) of the National Policy 12-203 – Cease Trade Orders the Company indicates it is unable to meet the prescribed filing deadline due to additional audit requirements by its auditor MNP, LLP and due to increased operational limitations related to the coronavirus pandemic. The Company continues to expect to file the annual filings, no later than July 15, 2020.

The Company intends to comply with the provisions of the alternative information guidelines as set out in the National Policy 12-203 – Cease Trade Orders for Continuous Disclosure Defaults for as long as it remains in default, including the issuance of bi-weekly default status reports, each of which will be issued in the form of a news release.

As required under Canadian securities laws, the Company will provide a further update on or about July 14, 2020. Additionally, to the knowledge of the Company, there have been no material business developments as of the date of this news release that have not been generally disclosed.

ABOUT EMPOWER

Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley

Chairman & CEO

[email protected]

604-789-2146

Investors: Dustin Klein

SVP, Business Development

[email protected]

720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding: the Company’s expected timing of filing of its Annual Filings, the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empowers patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond; the ability of the Company to complete or execute phases One, Two, Three or Four of COVID-19 test programs, and Psychedelic substances remain illegal in most countries, so please reference your local laws in relation to medical or recreational use. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

Spyder Cannabis $SPDR.ca Announces Receipt of RSA (“Retail Store Authorization”) for its Niagara Falls dispensary $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 8:56 AM on Tuesday, June 30th, 2020
  • Further to the announcement of receipt of a Retail Operator License (“ROL”), the Company is pleased to announce the receipt of its Retail Store Authorization (” RSA”) for its Niagara Falls dispensary located at 6474 Lundy’s Lane
  • The Company plans to begin operations at the location in July once the pre-opening inspection is completed, while ensuring it complies with COVID 19 provincial regulations and focusing on its curbside pickup and delivery business

Vaughan, Ontario–(June 30, 2020) –  Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder” or the “Company”) and its wholly-owned associated applicants, The Green Spyder Inc. and Spyder Cannabis Subco Inc., is pleased to provide the following update:

Niagara Falls Cannabis Dispensary

Further to the announcement of receipt of a Retail Operator License (“ROL”), the Company is pleased to announce the receipt of its Retail Store Authorization (” RSA”) for its Niagara Falls dispensary located at 6474 Lundy’s Lane. The Company plans to begin operations at the location in July once the pre-opening inspection is completed, while ensuring it complies with COVID 19 provincial regulations and focusing on its curbside pickup and delivery business.

About Spyder Cannabis Inc.

Spyder is a Cannabis, Vape and CBD retailer that operates in jurisdictions where the products are federally legal in both Canada and the United States. The Company, through its subsidiaries, is a retailer involved in the development of three retail business units. The first is the sale of Cannabis products, the second is the sale of Hemp CBD in the United States only, the third is the sale of smoking cessation products in Ontario.

Cautionary Statements

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release includes statements containing certain ‘forward-looking information” within the meaning of applicable securities laws (‘forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

Spyder Cannabis Inc.
Dan Pelchovitz
President & Chief Executive Officer
Telephone: 1.888.504.7737
Email: [email protected]